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INTRODUCTION 
 
Chemotherapy-induced ovarian failure not only 
increases the risk for early menopause-related 
complications but also results in infertility in young 
female cancer survivors [1,2]. In general, underlying 
mechanisms of this chemotherapy-induced ovarian 
aging is inadequately characterized in humans. 
 
The goal of this study was to explore the mechanism of 
the acceleration of human ovarian aging as a result of 
chemotherapy.  To investigate this effect we utilized a 
commonly administered cancer chemotherapeutic, 
doxorubicin, in an in vivo xenograft as well as in vitro 
models, using a double-species approach. DNA damage 
response induced by doxorubicin was assessed 
immunocytochemically by detecting histone H2AX 
phosphorylation on Ser139 [3] and activation of Ataxia 
Telangiectasia Mutated protein kinase (ATM) through 
its phosphorylation on Ser1981, using the respective 
phospho-specific Abs [4].  The extensive nuclear 
labeling with these Abs, especially in form of 
characteristic foci, is considered to report the presence 
of DSBs, the potentially lethal DNA lesions. 
 
METHODS 
 
This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of 
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Abstract: The mechanism of chemotherapy-induced acceleration of ovarian aging is not fully understood. We used 
doxorubicin, a widely used cancer chemotherapeutic, in a variety of in vivo xenograft, and in vitro models to investigate 
the impact of chemotherapy-induced aging on the human ovary.  Doxorubicin caused massive double-strand-DNA-
breaks in primordial follicles, oocytes, and granulosa cells in a dose dependent fashion as revealed by accumulating 
γH2AX foci. This damage was associated with apoptotic oocyte death and resulted in the activation of ATM. It appeared 
that the repair response enabled a minor proportion of oocytes (34.7%) and granulosa cells (12.1%) to survive while the 
majority succumbed to apoptotic death. Paradoxically, inhibition of ATM by KU-55933 resulted in improved survival, 
probably via prevention of downstream activation of TAp63α. Furthermore, doxorubicin caused vascular and stromal 
damage in the human ovary, which might impair ovarian function both pre- and post-menopausally. Chemotherapy-
induced premature ovarian aging appears to result from a complex process involving both the germ- and non-germ cell 
components of the ovary. These effects may have clinical implications in aging both for premenopausal and 
postmenopausal cancer survivors. 
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 Laboratory Animals of the National Institutes of Health 
and the New York Medical College (NYMC) 
Institutional Animal Care and Use Committee. The 
study protocol was approved by the institutional review 
board of NYMC and written informed consent was 
obtained from all participants involved in the study. All 
surgery was performed under anesthesia, and all efforts 
were made to minimize suffering. Ovarian tissue 
fragments were obtained from consenting females 
patients, or their parents in the case of minors, (n=6, age 
range 2-37) during ovarian tissue cryopreservation 
procedures before chemotherapy. 
 
The effect of doxorubicin was studied both with in vitro 
cultured human ovarian cortical tissue (OCT) and an in 
vivo human to severe combined immunodeficiency 
(NOG-SCID) (Taconic, USA) mice xenotransplantation 
model, as well as in in vivo mouse experiments. 
 
Human ovarian tissue culture 
 
OCTs were cut into 1mm
3
 pieces. They were then 
randomly selected and cultured in multi-well plates (# 
35-3078, Becton, Dickinson, NJ, USA) with MEM-
alpha medium (Gibco, Invitrogen, Carlsbad, USA) 
supplemented with 10% bovine serum albumin 
(v/v)(Sigma-Aldrich, St. Louis, MO, USA) and 1% 
insulin-transferrin-selenium (Gibco, Invitrogen, 
Carlsbad, USA) containing 1, 10 and 100 µg/ml of 
doxorubicin (Sigma-Aldrich, St Louis, MO, USA) for 
24-72h (n=8 in each experimental point). In controls, 
vehicle (sterile normal saline) was added to the culture 
medium in control group. Cultured OCT samples were 
recovered and processed for further histological 
evaluation. 
 
Human ovarian tissue xenografting 
 
OCT pieces (1mm
3
) were selected randomly and 
transplanted into the dorsal muscles of seven-week-old 
SCID mice (NOG, Taconic, USA) as previously 
described (13-16) (n=8). Briefly, human ovarian 
fragments were collected in modified M199 medium 
(Gibco, Invitrogen, Carlsbad, USA). Recipient animals 
were anesthetized by ketamine 75 mg/kg i.p. 
(Ketathesia, OH, USA) and xylazine 1 mg/kg i.p. 
(AnaSed, Shanandoah, Iowa, USA) [5]. A small 
incision was made in the skin on the dorsal midline of 
the recipient animal, and OCT pieces (n=2/animal) were 
transplanted into the dorsal muscles in recipient mice by 
means of a fine watchmakers’ forceps. Skin incision 
was closed under aseptic conditions. Animals were 
allowed to recover for ten days and 10 mg/kg 
doxorubicin was administered to the xenografted 
animals intravenously. In contrast, control animals were 
treated with vehicle. OCT grafts were recovered 24h 
later and analyzed for vascular density by CD31 
expressing micro-vessels/mm
2 
field, percentage of 
primordial follicles with DSBs by γH2AX staining and 
those that are apoptotic by AC3 expression. 
 
In vivo assessment of the impact of doxorubicin in 
the mouse ovary   
 
Due to the non-uniformity of human primordial follicles 
distribution in OCTs, the number of primordial follicles 
and apoptotic follicles densities were compared in 
ovaries of doxorubicin-treated SCID mice compared to 
vehicle-treated controls (n=6). 
 
Furthermore, to study the in vivo effect of doxorubicin 
on ovarian follicles and their cumulus cells, mice (n=7) 
(B6D2 and FBV, Taconic, USA) were injected with a 
single dose of doxorubicin 10 mg/kg. Animals were 
sacrificed 24h later, ovaries were collected, small 
preantral follicles (100–120 µm in diameter) (n=140) 
and GV oocytes (n=94) were mechanically isolated by a 
fine needle (25 5/8-G; Becton–Dickinson NJ, USA) and 
fixed in 4% of methanol-free formaldehyde dissolved in 
phosphate buffered saline (PBS) washed and stored in 
blocking solution. Blocking solution was composed of 
2% (v/v) normal goat serum (Gibco, Bornem, Belgium), 
0.2% (w/v) powdered milk (Bio-Rad, Hercules, CA, 
USA), 1% (w/v) bovine serum albumin (BSA, Sigma-
Aldrich, St. Louis, MO, USA), 0.1M glycine (Bio-Rad), 
0.01% Triton X-100 (Bio-Rad), in PBS (Calbiochem, 
Darmstad, Germany) with 0.2% sodium azide (Sigma-
Aldrich,). Oocytes and follicles were evaluated with 
laser scanning confocal microscopy (LSM170, ZEISS, 
Imager Z1) using a Zen 2008 imaging program, after 
being stained for anti-active-Caspase-3 (AC3, R&D 
systems, Minneapolis, USA), phospho-ataxia-
telangiectasia-mutated (ATM, Millipore, Temecula, 
CA, USA) and γH2AX (BioLegend, San Diego, CA, 
USA). The percentage of granulosa cells from small 
preantral follicles positive for DSBs by γH2AX, 
apoptotic by AC3, and the ATM expression were 
compared to vehicle-treated controls. Vehicle-treated 
animals served as control. The extent of DSBs was 
further investigated by single cell gel electrophoresis 
(Comet assay) [6]. Briefly, GV oocytes were obtained 
and the granulosa cells were removed enzymatically by 
short incubation in hyaluronidase and the zona pellucida 
was removed by incubation in acid Tyrode`s solution.
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Following the lysis of the oocytes with detergent at high 
salt concentration, electrophoresis was performed at 
neutral PH to facilitate the detection of DSBs (7.4). 
Chromatin staining was performed with propidium 
iodide. The extent of DNA migration was quantified 
using comet score program (TriTech Corporation, 
Sumerduck, VA, USA) and expressed as the percentage 
of DNA in the tail and compared with non-doxorubicin-
treated oocytes. All the products used for this 
experiment were bought from Sigma-Aldrich, St. Louis, 
MO, USA, unless otherwise mentioned. 
 
Ovarian tissue histology and immunohistochemistry 
 
OCT samples were recovered and processed for 
hematoxylin-eosin staining (H&E) and 
immunohistochemistry (IHC) with activated caspase-3 
(AC3) antibodies for the detection of apoptosis.  The 
number of apoptotic follicles was expressed as the 
fraction of total follicle numbers in each square 
millimeter of tissue. Tissues were also evaluated for the 
presence of new (CD31, Abcam, MA, USA) and 
existing mature blood vessels (alpha smooth muscle 
actin) (α-SMA, Ventana, Lille, France) by IHC staining. 
Blood vessels were counted and averaged at high power 
field magnification (×400) in a grid area of 0.15 mm
2 
at 
five randomly selected positions in twenty-five different 
sections of each tissue sample [5,7]. The presence of 
characteristic nuclear foci after immunostaining for 
γH2AX (Bethyl Laboratory, Montgomery, TX, USA) 
was considered to represent the induction of DSBs and 
the percent of oocytes expressing distinct γH2AX foci 
was visually assessed under microscope.   
 
Figure 1. Induction of double strand DNA breaks in human primordial follicles by doxorubicin. γH2AX-
positive (black arrows) and negative (white arrows) primordial follicles in human ovarian cortical pieces after in 
vitro culture with doxorubicin doses of 1-100 mg/ml for 24 or 72h. A-C) Doxorubicin induces DSBs in a dose-
dependent fashion after 24h of culture. Note the massive induction of DSBs in primordial follicles after 24h 
culture with doxorubicin 100 mg/ml. D) Vehicle control at 72h. E-G) Doxorubicin treatment at 100 mg/ml for 72h 
also causes ovarian tissue necrosis along with massive γH2AX expression in stromal cells. H) Negative control, 
secondary antibody omitted. I) Induction of DSBs was positively correlated with the dose of doxorubicin after 24-
72h culture (Spearman`s rank correlation coefficient: 0.967; p<0.001). J) High number of γH2AX-positive 
primordial follicles in a xenograft from a SCID mouse treated with 10mg/kg doxorubicin. K) Vehicle-treated 
(control) human ovarian tissue xenograft. 
# Significantly different from the control 24h 
*Significantly different from the control 
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Statistical analysis 
 
SPSS 17 for Windows package (SPSS Inc., Chicago, 
IL) was used for statistical analysis. To choose the 
appropriate statistical test, Levene’s test of homogeneity 
of variances (p<0.01) and Kolmogorov-Smirnov test of 
normality (p<0.01) were performed. Continuous data 
(presented as mean±SD) were analyzed by one-way 
analysis of variance followed by the LSD post hoc test. 
The non-parametric data were analyzed with the 
Kruskal-Wallis test followed by multiple pair-wise 
comparisons using Mann-Whitney U-test (α value was 
adjusted). To analyze the relation between two 
categorical variables, Fisher’s exact test was performed. 
Non-parametric correlation between the percentage of 
apoptotic follicles and the number of blood vessels was 
analyzed with the Spearman’s test. The difference was 
considered statistically significant if the P value was 
<0.05. 
 
RESULTS 
 
Doxorubicin induces double strand DNA breaks in 
human ovary as reported by γH2AX expression 
 
For in vitro experiments, human ovarian cortical pieces 
were cultured for 24-72h with or without doxorubicin at 
1, 10, 100 µg/ml doses and primordial follicle densities 
were compared. The presence of γH2AX, the reporter of 
DSBs [3,4] and primordial follicle apoptosis, detected 
by the activated caspase-3, were studied in adjacent 
OCT sections. A significantly higher percentage of 
γH2AX-positive primordial follicles were observed in 
OCTs incubated with 1 µg/ml doxorubicin for 24h in 
comparison to vehicle-treated controls (45.2±7.3 vs. 
26.5±2.9 %, p=0.005) and 72h (53.2±1.7 vs. 31.7±4.5 
%, p<0.001) (Figure 1, A-H). Treatment with 10 µg/ml 
doxorubicin resulted in a significantly higher percentage 
of γH2AX-positive primordial follicles both after 24h 
(77.5±7.4 %, p<0.001) and 72h (96.2±7.2 %, p<0.001) 
compared to control. Doxorubicin 100 µg/ml induced 
massive γH2AX labeling in ovarian follicles regardless 
of the incubation time (94.8± 2.4 and 99.1±1.7 %, 24h 
and 72h respectively, p<0.001). A significant 
correlation was observed between the dose of 
doxorubicin and the percentage of γH2AX-foci positive 
primordial follicles in cultured OCTs (Spearman`s rank 
correlation coefficient: 0.967; p<0.001) (Figure 1, I). 
 
To translate the in vitro findings to the in vivo setting, 
SCID mice were xenografted with human ovarian tissue 
and received 10 mg/kg of doxorubicin as described in 
the methods section. Doxorubicin treatment resulted in 
a significantly higher percentage of γH2AX-positive 
Figure 2. Induction of apoptotic primordial follicle death by doxorubicin. AC3-positive (black arrows) 
and negative (white arrows) primordial follicles and apoptotic vasculature (red arrow) in human ovarian cortical 
pieces. A-D) Doxorubicin induces apoptosis of human primordial follicles after 24h culture in 10 and 100 μg/ml 
concentrations. E) Vehicle control at 72h. F) Negative control are shown where primary antibody omitted. G) A 
significant correlation was observed between the dose of doxorubicin and percentage of apoptotic primordial 
follicles in cultured OCTs (Spearman`s rank correlation coefficient: 0.785; p=0.0001). H) A high number of 
apoptotic primordial follicles was seen in human ovarian tissue xenografted into the dorsal muscle of SCID mouse 
after treatment with 10mg/kg doxorubicin. I) Xenogafted vehicle-treated control. 
*Significantly different from controls at 24 or 72h. 
#
Significantly different from 1 µg/ml doxorubicin dose at 24 and 72h. 
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 primordial follicles compared to vehicle treatment 
(58.1±1.0 vs. 15.6±0.9 %, p<0.001) (Figure1, J and K). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Doxorubicin induces apoptotic death of human 
ovarian follicles 
 
Doxorubicin caused apoptosis in a dose-dependent 
manner when evaluated by AC3 staining in vitro 
(Figure 2, A-F). The percentage of follicles undergoing 
apoptosis increased at both 10 and 100 µg/ml but 
statistical significance was noted only with the 100 
µg/ml dose of doxorubicin after 24 and 72h of culture 
(57 and 59 % of follicles in doxorubicin-treated vs. 14 
and 25 % in vehicle-control at 24h and 72h, 
respectively, p<0.001). A significant correlation was 
observed between the dose of doxorubicin and the 
percentage of apoptotic primordial follicles in cultured 
OCTs (Spearman`s rank correlation coefficient: 0.785; 
p=0.0001)(Figure 2, G).  
 
Consistent with in vitro findings, in vivo doxorubicin 
treatment induced a significantly higher level of 
apoptosis in xenografted primordial follicles (55.4±5.7 
vs. 11.8±5.7 %, p<0.005) treated with doxorubicin 
compared to vehicle-treated controls (Figure 2, H and 
I). In addition, the ovaries of SCID mice that were used 
in the human xenografting experiments showed that 
doxorubicin treatment significantly reduced the mean 
density of primordial follicles (4.31±2.1 vs. 
10.57±6.7/mm
2
, p<0.001) compared to vehicle-treated 
controls similar to its effect in human ovarian 
xenografts in the same mice, doxorubicin treatment also 
induced a significantly higher percentage of apoptotic 
follicles in primordial (47.1±12.8 vs. 0.4±1.4 %, 
p<0.001), primary (44.7±12.2 vs. 4.1±5.9 %, p<0.001) 
and developing (49.5±8.6 vs. 6.9±5.5 %, p<0.001) 
follicles as well as inducing  γH2AX expression  
(Figure 3). In these follicles, co-expression of AC-3 and 
γH2AX suggested that unrepaired DSBs were resulting 
in apoptotic death. 
 
Doxorubicin causes microvascular and stromal 
damage in human ovary 
 
The density of newly forming ovarian microvessels was 
determined by CD31-expression in micro vessels per 
mm
2 
after treatment with doxorubicin. The results 
showed a decrease in vascular density with the 72h 
culture after 1 µg/ml (26.5±8.4/mm
2
, p<0.001), 10 
µg/ml (25.5±7.8/mm
2
, p<0.05), and 100 µg/ml 
doxorubicin (20.8±5.1/mm
2
, p<0.05) compared to 
vehicle treatment (39.4 ±5.7/mm
2
)(Figure 4, A-D). In 
contrast, blood vessel density increased significantly 
after 72h culture in vehicle-treated controls compared to 
the uncultured baseline tissue (39.4±5.7/mm
2
 vs. 
30.0±6.2/mm
2
, p<0.001), (Figure 4, D and E), due to 
expected continuation of microvessel proliferation. 
There was also a significant decrease in the density of 
mature blood vessels as determined by αSMA IHC after 
72h culture with 10 µg/ml (4.0±2.0 vs. 9.5±3.5, 
p=0.002) and 100 µg/ml doxorubicin (4.7±3.1 vs. 
9.5±3.5, p=0.04) compared to controls. A significant 
inverse-correlation was observed between the dose of 
doxorubicin and the density of αSMA-positive vessels 
(Spearman`s rank correlation coefficient: -0.798; 
p<0.001)(Figure 4, F). Furthermore, after 72h culture 
with doxorubicin 1, 10 and 100 µg/ml, multiple necrotic 
areas were seen in OCTs (7.3±5.1, mean number of 
necrotic areas/graft)(Figure 4, G). Validating and 
confirming in vitro organ culture experiments, 
doxorubicin treatment also resulted in reduced vascular 
density in xenografted human ovarian tissues compared 
to vehicle-treated controls (6.4±1.9 vs. 13.9±2.1, 
p<0.001)(Figure 4, H and I). 
 
Figure 3. Induction of DSBs and apoptotic follicle death 
by doxorubicin in xenografted SCID mouse ovaries. 
Ovaries of xenografted SCID mice were recovered 24h after a 
single injection of doxorubicin 10 mg/kg and stained for  γH2AX 
and AC3. A) γH2AX-positive primordial follicle oocytes 
(highlighted) in lower magnification. Note γH2AX staining in 
granulosa cells but not the oocyte of the adjacent preantral 
follicle. B) Higher magnification of the primordial follicle in solid 
square with yH2AX staining. C) The same primordial follicle in B 
shows AC3-positive staining on the adjacent section, suggesting 
that DSBs induced apoptotic follicle death. D) Negative control. 
Primary antibody omitted, same follicle as in B & C, on adjacent 
section, E) Higher magnification of γH2AX-positive primordial 
follicle from panel A, in dashed square. F) AC3-positive staining 
of the same follicle in D on adjacent section. 
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Doxorubicin induces γH2AX in immature (GV) mice 
oocytes and small ovarian preantral  follicles, while 
activating ATM-pathway response 
 
To further delineate and confirm the impact of 
doxorubicin on double strand DNA and the involvement 
of ATM-mediated DSB repair response, GV oocytes 
and small preantral follicles were collected from the 
ovaries of doxorubicin- or vehicle-treated mice and 
evaluated by confocal microscopy. A significantly 
higher number of GV oocytes in doxorubicin-treated 
animals demonstrated multi-nucleation compared to 
vehicle-treated controls (28.2±6.0 vs. 4.9±4.0, p 
<0.001) (Figure 5, A and B) consistent with chromatin 
damage and genotoxicity [8,9]. In parallel with multi-
nucleation, the mean number of γH2AX foci (64.1±29.8 
vs. 11.5±7.3, p<0.05) and the percentage of apoptotic 
follicles (42.7±11.6 vs. 2.7±3.8, p<0.05) were 
significantly higher in GV oocytes from doxorubicin-
treated ovaries compared to vehicle-treated controls 
(Figure 5, C and D). 
 
The comet assay is based on the ability of negatively 
charged fragments of DNA to move through an agarose 
gel in response to an electric field. The extent of DNA 
migration depends directly on the DNA damage present 
in the cells. The alkaline version of the comet assay 
enables the detection of DNA single-strand breaks and 
alkali-labile lesions (DNA breaks that only become 
apparent after exposure to alkali) while electrophoresis 
at neutral conditions detects DSBs[6]. To confirm that 
increased γH2AX foci reflected DSBs, we performed a 
neutral pH comet assay on GV oocytes treated in vitro 
with doxorubicin 10 µg/ml. for 24h and found similar 
results (Fig 6). 
 
Having shown that doxorubicin causes DSBs resulting 
in apoptotic death in oocytes, we next studied the DNA 
repair response. To study the DNA repair response, we 
analyzed expression of activated ATM. Compared to 
vehicle-treated controls, doxorubicin treatment 
increased ATM activation both in the nucleus (7.1±1.4 
vs. 224.5±42.2, p<0.001) and the cytoplasm 
(142.2±30.1 vs. 186.3±27.6, p<0.05) (Figure 5, E and 
F). Moreover, the same treatment caused a change in 
the localization of ATM. While in control oocytes the 
predominant fraction of ATM was in the cytoplasm 
(142.2±30. vs. 7.1±1.4 in nucleus, p<0.001) after 
doxorubicin treatment (Figure 5, E), a larger proportion 
was located in the nucleus (224.5±42.2 vs. 186.3±27.6 
in cytoplasm, p<0.05)(Figure 5, F). The latter indicates 
a significant translocation of phospho-ATM from 
cytoplasm to nucleus. 
 
Unrepaired DSBs will result in the activation of 
apoptotic pathways via the ATM-pathway [10] or cell 
cycle arrest [11]. We therefore assessed the relationship 
between γH2AX staining and apoptotic oocyte death. 
Of the γH2AX-positive oocytes, 66.3 ±12.8% were 
apoptotic and the remainder were non-apoptotic based 
Figure 4. The impact of doxorubicin on vascular density in ovarian cortical pieces. A-C) CD31-positive 
blood vessels in human ovarian cortical pieces cultured with different doses of doxorubicin for 72h. Doxorubicin 
treatment results in decreased density of blood vessels in a dose dependent manner. Vehicle-treated control. E) 
CD31-positive blood vessels are shown at baseline in ovarian tissue. F) Doxorubicin caused a significant decrease 
in ovarian vascular density after 72h for all doses but not 24h culture compared to controls at all three doses 
tested. G) Doxorubicin-induced necrosis and stromal cell death in vitro (red arrow). H&I) Similar to in vitro 
experiments, doxorubicin reduced vascular density in xenografts compared to vehicle-treated control xengrafts. 
Black arrows show CD31-positive blood vessels in human ovarian cortical pieces. 
*Significantly different from the control (72h). 
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 on AC-3 staining. This suggests that either the DNA 
damage was not sufficient to induce cell death, or DNA 
repair mechanisms were successful and prevented cell 
demise. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To demonstrate that ATM activation was involved in 
and is related to oocyte survival or apoptotic death after 
doxorubicin-induced DNA damage, we pretreated  
mouse GV oocytes with ATM inhibitor KU-55933, 10 
μMol (Tocris Bioscience, Missouri, USA) or its vehicle 
(dimethyl sulfoxide, Sigma) for 3h prior to doxorubicin 
treatment (1 μg/ml). Oocyte apoptosis was assessed 24h 
later. In the ATM-inhibited group, percentage of 
apoptotic oocytes was significantly reduced compared 
to the non-ATM-inhibited (28.6% vs. 64.1%; p<0.05). 
These data indicate that ATM activation is involved in 
chemotherapy-induced oocyte death and is consistent 
with the previous data in lymphoblastoid cells that 
inhibition of ATM rescues from tumor necrosis factor- 
related apoptosis-inducing ligand induced apoptotic 
death [12]. Interestingly, doxo treatment blocked cell 
cycle progression beyond Metaphase I (MI) stage but 
ATM inhibitor treatment did not significantly affect this 
inhibition. One hundred percent in the doxo group and 
92.1% in the doxorubicin+ATM inhibitor group 
arrested at GV or MI compared to 17.7% in the control 
group after 24h in culture (P<0.001). 
 
TAp63α is involved in female germline survival and 
ATM has been shown to regulate c-Abl-TAp63 
pathway[13,14,15]. Thus we wanted to determine 
whether the reduction of doxo-induced apoptotic death 
of oocytes in response to the ATM inhibitor was due to 
prevention of ATM-induced activation of the c-Abl-
TAp63 pathway. By confocal imaging, we found that 
ATM inhibition with KU-55933 also inhibited TAp63 α 
and c-Abl activation in the nuclei of doxo-treated 
oocytes (supplementary figure 1). The inhibition of 
TAp63 was more profound, with KU-55933 completely 
blocking phosphorylation of TAp63 in response to 
genotoxic effects of doxorubicin. This suggests that 
ATM is regulating TAp63 α activation both c-Abl 
dependent and independent pathways, the latter being 
the predominant form. 
 
Doxorubicin treatment also resulted in a significant rise 
in the percentage of apoptotic cumulus cells 
surrounding the oocytes compared to controls 
(27.7±10.3 vs. 2.4±0.6, p<0.001) (Figure 5, C and D). 
Thus we also studied cell survival and DNA damage in 
granulosa cells of small follicles isolated from 
doxorubicin-treated mice. Consistent with its effect in 
GV oocytes, doxorubicin compared to vehicle 
treatments resulted in a significant increase of cells 
expressing γH2AX (53.8±12.3 vs. 2.1±0.4, p<0.001) 
and induction of apoptosis in granulosa cells 
(35.9±14.6% vs. 3.7±2.0%, p<0.001)(Figure 5, G-J). In 
doxorubicin-treated follicles  higher percentage of 
granulosa cells expressed activated ATM (57.5±17.8 vs. 
0.9± 0.7, p<0.001). A fraction of granulosa cells that co- 
Figure 5. Doxorubicin induces double strand DNA 
breaks, activates ATM, and causes apoptosis in mouse 
oocytes. To study the in vivo effect of doxorubicin on mouse 
ovarian follicles and their cumulus cells, animals were injected 
with a single dose of doxorubicin 10 mg/kg. GV oocytes and 
small preantral follicles were retrieved 24h later from ovaries 
and evaluated by confocal microscopy. A&B) Doxorubicin 
treatment leads to multinucleation as well as increased 
expression of γH2AX. C&D) Doxorubicin-induces apoptosis of 
the oocyte and surrounding granulosa cells (arrows) in 
association with the induction of DSBs. E&F) Expression and 
localization of ATM in oocytes after doxorubicin treatment. 
While a higher amount of ATM is localized in the cytoplasm (cy) 
of the control oocytes (E), doxorubicin-treated oocytes show 
higher localization in the nucleus(nu)(F). G) Consistent with its 
impact on oocytes, ATM expression also increases in granulosa 
cells of small antral follicles after doxorubicin treatment (yellow 
arrows). H) Note that doxorubicin treatment induces DSBs in 
granulosa cells of small antral follicles (Split  channel from 
image G). I) A minority of granulosa cells are non-apoptotic and 
express ATM indicating that DNA repair might have enabled 
them to overcome genotoxic stress (yellow arrows) (split 
channel from image G). J) The majority experience apoptosis 
despite the activation of ATM (split channel from image G). 
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expressed ATM and γH2AX were not apoptotic (12.1± 
5.9%) suggesting that ATM-mediated repair process 
was still ongoing and probably preventing cell death 
(Figure 5, I). In majority however, apoptosis coincided 
with the co-expression of ATM and γH2AX (Figure 5, 
J), indicating that the DNA repair response was not 
sufficient to rescue granulosa cells from chemotherapy-
induced death. 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Doxorubicin is a key chemotherapeutic agent used in 
the treatment of numerous malignancies such as breast, 
ovarian, and endometrial cancers as well as lymphomas, 
acute leukemias, and many others which are commonly 
encountered during the premenopausal ages 
[16,17,18,19]. In the present study we investigated the 
mechanism of chemotherapy-induced ovarian aging 
induced by this drug in vitro and in vivo on human and 
mice ovaries.  
 
We found that doxorubicin, in a dose-dependent 
fashion, caused massive induction of γH2AX, likely 
reporting formation of DSBs in human and mouse 
oocytes, as confirmed by the presence of multi-
nucleation (Fig. 5 A&B)  and comet assay 
(Supplementary figure 1). The induction of DSBs was 
associated with apoptotic death of primordial follicles 
upon exposure to doxorubicin. Doxorubicin activated 
ATM-mediated DSB repair pathways, which involved 
H2AX phosphorylation and most likely activation of 
other signaling pathways associated with DNA damage 
response [4]. It seems that following DNA damage not 
only expression of activated ATM was increased but 
there was a significant translocation from the cytoplasm 
to the nucleus. Although ATM was originally thought to 
be a nuclear protein in proliferating cells, in oocytes it is 
predominantly cytoplasmic [20]. To our knowledge, this 
is the first observation of activated ATM behavior in 
oocytes. Further laboratory research will be needed to 
determine the function of cytoplasmic ATM and the 
significance of the translocation process to ATM 
function in response to genotoxic stress. 
 
It is clear that the extent of doxorubicin-induced DNA 
damage is sufficient to induce apoptotic death of the 
majority of human and mouse primordial follicles. 
Apparently the repair mechanisms were inadequate to 
Figure 6. Comet assay with murine GV oocytes. Double strand DNA breaks were detected in murine GV 
oocytes using a single cell gel electrophoresis (Comet assay) after 24h culture with or without doxorubicin (10 
µg/ml).  Representative images of non-treated (A) and doxorubicin-treated (B) oocytes are shown. (C) 
Quantification of DNA damage in control versus doxorubicin treated oocytes; expressed as mean (± SD) % of DNA 
in the tail. P = 0.002 (t-test). 
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Supplementary Figure 1. ATM inhibitor KU-55933 blocks 
activation of p63 in mouse oocytes response to genotoxic stress. 
Germinal vesicle stage oocytes from 6 week old FVB mice (n=14-
16/group) were treated without or with doxorubicin (1 μg/ml) 
for 24h in the presence or absence of KU-55933 (10 μMol) and 
were subjected to confocal microscopy. Signal intensity for 
phospho-c-Abl (A) and phospho-TAp63 (B) were quantified using 
ImajeJ software (arbitrary units, AU). (A) KU-55933 inhibits 
doxo-induced activation of c-Abl (p<0.05) but not the basal 
levels of phospho-c-Abl; (B) KU-55933 completely blocks 
activation of p63 (p<0.05) both in non doxo-treated (p<0.05) 
and doxo-treated (p<0.05) oocytes. * indicates statistically 
significant difference from the doxo only group. 
 rescue them. Our findings, however, also suggest an 
intriguing possibility that the activation of ATM may 
result in the rescue of a considerable minority of 
oocytes which have sustained DSBs due to 
chemotherapy. While the ATM-mediated DSB repair 
pathway is of high fidelity in nature and the majority of 
oocytes which were made to survive by this mechanism 
should have their DNA integrity restored, miss-repair or 
survival despite a failed repair is still possible[21]. This 
novel concept is supported by our demonstration of 
reduction of chemotherapy-induced apoptotic death 
after the treatment of oocytes with ATM inhibitor KU-
55933.  While in somatic cells, inhibition of DNA 
repair mechanisms may be expected to increase 
sensitivity to chemotherapeutics in general [22], germ 
cells seem to have a different behavior. In oocytes, 
TAp63α, a pro-apoptotic P53 family member with 
specificity to germ line, is activated in response to DNA 
damage and causes apoptotic death [13,15]. TAp63α is 
activated by c-Abl, which is a non-receptor tyrosine 
kinase involved in many cellular processes, in response 
to DNA damage. It has been shown that ATM is 
involved in activation of c-Abl after DNA damage [14]. 
Our finding that ATM inhibition reduces apoptotic 
oocyte death after DNA damage, while blocking 
TAp63α and c-Abl activation, is consistent with ATM’s 
role in activation of the c-Abl-TAp63 pathway. We 
found that ATM inhibition had a more profound 
negative effect on  Tap63α activation than c-Abl (Suppl. 
Fig. 1), suggesting that ATM might also be regulating  
doxo-induced TAp63α  activation independent of c-Abl 
in oocytes. Our findings are also in parallel with the 
data showing that ATM has a pro-apoptotic function in 
DNA-damaged neurons of developing mouse CNS, in 
collaboration with the Bax protein [23,24,25,26,27].  It 
was observed in these previous studies that ATM−/− 
mice exhibited resistance to ionizing radiation-
induced apoptosis in diverse regions of the 
developing CNS. In wild-type but not ATM−/− mice, 
up-regulation of p53 coincided with cell death, 
suggesting that ATM-dependent apoptosis in 
the CNS was mediated by p53. Furthermore, p53-null 
animals exhibited similar lack of radiation-induced cell 
death in the developing nervous system. These results 
are in correlation with our findings in the ovary, and 
suggest that ATM may function at a developmental 
survival checkpoint that serves to eliminate cells with 
excessive DNA damage[23,25,26] [27,28] . 
 
This brings the next question of whether unrepaired or 
mis-repaired DSBs can culminate into severe mutagenic 
changes in the surviving primordial follicles. Even 
though clinical data do not suggest an increase in the 
incidence of genetic disorders in children born to cancer 
survivors, the power of such studies is limited [29,30]. 
Of concern, a recent rodent study showed increased 
rates of neonatal death, physical malformations, and 
chromosomal abnormalities in up to 6 generations of 
offspring after exposure to single dose of doxorubicin 
[31]. Because unrepaired DSBs can result in severe 
mutagenesis and can explain these new findings in 
laboratory animals, it will be of great importance to 
study the accumulation of DSBs in long term human 
ovarian xenografting experiments as well as in vivo in 
mice.  However, we found from our in vitro 
experiments with mouse oocytes that even though ATM 
inhibition rescued oocytes from chemotherapy-induced 
death, it did not prevent the arrest of their growth at M-I 
stage. This indicates that there are cell cycle check 
mechanisms independent of ATM which can sense 
lethal DNA damage and prevent propagation of severe 
mutations. It is possible that in humans too, even though 
some primordial follicles may survive chemotherapy 
exposure despite the presence of significant DSBs, their 
growth may be halted after ovulation triggers the 
resumption of cell cycle from prophase-I. Because cell 
cycle check mechanisms would prevent such oocytes 
from becoming mature and advancing to M-II stage, 
they cannot be fertilized to become embryos. This 
hypothesis is consistent with our previous clinical 
findings that women with seemingly normal ovarian 
reserve post-chemotherapy have significantly lower 
pregnancy rates with in vitro fertilization compared to 
age-matched controls [32].  Hence women whose 
ovarian function has survived chemotherapy may still 
be at risk for infertility due to this occult DNA damage 
in their remaining oocytes. 
 
Why some ovarian follicles die after chemotherapy 
while others survive in the same environment? It is 
possible that some oocytes may survive chemotherapy 
without DNA damage due to their individual resistance 
to chemotherapy through yet undefined mechanisms.  
One such possible mechanism is the difference in the 
efficiency of DNA repair in individual oocytes. Data are 
already accumulating that effective DSB repair is vital 
for oocyte survival [33]. It is possible that those oocytes 
which inherently are more efficient in DNA repair are 
more likely to be resistant to chemotherapy-induced 
DSBs and cell death. The opposite is also possible that 
the absence of ATM response is responsible for the 
perceived survival of ovarian follicles after 
chemotherapy. From our experiments showing that 
ATM inhibition reduces apoptotic oocyte death, it can 
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 be speculated that some oocytes that survive despite 
chemotherapy exposure might have deficient ATM 
response, which fails to initiate TAp63α dependent 
death, allowing survival despite the persistence of 
DSBs. If such individual differences exist, exploration 
of factors regulating DSB repair in oocytes may result 
in the development of new therapeutic strategies to 
protect oocytes by enhancing DNA repair efficiency 
and preserve fertility in the face of chemotherapy. 
 
It should be noted the survival of primordial follicles 
was presently observed at relatively short time (24–72 
h) of exposure to chemotherapy in organ cultures or 
xenografts (figs 2 and 3). It is possible that some of the 
“surviving” oocytes were actually undergoing cellular 
senescence, the state of reproductive cell death with 
preservation of physical and metabolic integrity [34]. In 
fact, the mechanism of chemotherapy-induced growth 
inhibition of tumors often involves  both, induction of 
apoptosis and irreversible impairment of cell 
reproductive capacity, defined as “senescence-like 
growth arrest”,  “premature senescence”  or “drug-
induced senescence” [34,35,36]. Further research will 
be needed to determine whether meiotic cells i.e. 
oocytes can also experience this form of senescence. 
 
Another novel finding from our studies is the ability of 
doxorubicin to damage human ovarian 
microvasculature. We found that doxorubicin causes a 
decline in microvascular density in a dose-dependent 
fashion. While we cannot prove that microvascular 
damage directly contributes to chemotherapy-induced 
follicle death, in prior studies we showed an inverse 
correlation between human ovarian microvascular 
density and primordial follicle apoptosis[5]. It is 
generally believed that the human primordial follicles 
are not acutely dependent on perfusion but the clinical 
experience from ovarian transplantation[37]  as well as 
acute ovarian ischemia (ovarian torsion) cases do not 
support this general belief[38] . While larger follicles 
may be more sensitive to acute ischemic changes due to 
a greater mass of proliferating granulosa cells, our 
experimental models clearly support the dependence of 
primordial follicles on adequate vascularization [5]. 
Given this background, it is possible that chemotherapy-
induced ovarian vascular damage is a contributing 
factor to the loss of primordial follicle reserve and aging 
in human ovary.   
 
Furthermore, ovarian tissue is a functional endocrine 
organ even after natural menopause or premature 
ovarian failure, and continues to produce critical sex 
steroids such as testosterone and estrogen. We not only 
showed that doxorubicin-induces microvascular damage 
but it also damages ovarian stroma. Hence it is likely 
that even as a postmenopausal senescent organ, the 
human ovary becomes dysfunctional after 
chemotherapy. In keeping with this concept, we 
previously showed that chemotherapy exposed ovarian 
stromal tissue produces lower levels of estradiol 
compared to controls [39]. 
 
Our findings have strong clinical implications. A large 
number of young females receive doxorubicin as part of 
their treatment for cancer. Doxorubicin treatment may 
not only be compromising the future fertility potential 
and accelerating ovarian aging in these young cancer 
survivors but can also be placing them at disadvantage 
during their postmenopausal years. Women undergoing 
chemotherapy with doxorubicin containing regimens 
must undergo adequate counseling to weigh their 
options for established and experimental fertility 
preservation options [40](9). While oocyte and embryo 
cryopreservation can be utilized to preserve future 
fertility, ovarian cryopreservation for future 
transplantation is the only modality that can restore 
natural ovarian function and circumvent chemotherapy-
induced premature ovarian senescence [41,42]. Given 
our findings that the chemotherapy-exposed human 
ovary may not function as a normal postmenopausal 
organ and show accelerated senescence, ovarian tissue 
freezing may be selectively attractive to some survivors. 
More importantly, given these complex damaging 
effects of cancer drugs on human ovarian function, less 
toxic drugs should be developed, or elected when they 
are available. And finally, understanding the mechanism 
of accelerated senescence by cancer drugs may enable 
us to develop targeted pharmacological ovarian 
preservation methods. 
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